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Introduction
Familial Mediterranean fever is the most periodic fever
sendrome and characterized by reccurent fever, abdominal
pain, chest pain, arthritis/ arthralgia and erizipel like rash
and self limited attacks with fever and serozal inflomation
also elevated acute phase reactants. As with other chronic
inflammatory diseases in patients with AAA growth may
be negative effects.
Objectives
The aim of the study was to evaluate the growth para-
meters after treatment with colchicine in patients with
newly diagnosed by examining prepubertal, along with
other identifying characteristics of the disease, taking into
account the status of inflammation subclinic to investigate
the effects on the growth of disease severity and activity.
Methods
In the study, patients’ disease activity, attack frequency,
colchicine dose, laboratory studies of control, height and
weight which measured with a standard stadiometre, were
recorded by a standard person. Growth rates detected by
determining the height and weight SDS ‘s (Z-score) with
an interval of six months. All measurements and evalua-
tions were made on 51 prepubertal patient.
Results
Patients, 22 (43.1%) were male and 29 (56.9%) were female
with age of disease onset 5 (1-10) years, age of diagnosis
and onset of therapy were 6.4 (1.3 to 11) years. According
to Tel Hashomer criteria, severity score of the disease was
7 (4-10). When compered of height and weight of the
patients at the beginning and at the one year of colchicine
treatment a significant increase was found (p<0,05).
Height SDS ‘s increased from -0.6 to -0.2; weight SDS’ s
increased from -0.6 to -0.4. The participants’ BMI SDS
didn’t showed a significant increase, both the weight and
height SDS proceedings of the increase was associated
with, so it is possible there was no significant increase.
The patients’, who had no episode, height and weight SDS
increased more than who had episode. There was no effect
of disease severity on growth (p> 0.05). Also height gain
was not affected from elevated acute phase reactans at
the attack free period, weight gain did. Body weight
and body surface of the patients receiving doses of colchi-
cine were averaged 0.03 ± 0.02 mg / kg / day was 0.98 ±
0.045 mg/m2. Colchicine dose was the same in patients
with or without any attack.
Conclusion
In this study, the positive effects of colchicine on the
growth in prepubertal patients with newly diagnosed AAA
was found. The prevention clinical episodes was enough
for height growth but the prevention clinical episodes and
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